JP5990254B2 - 代謝活性プロフィルのモニタリング方法および分析方法ならびにそれらの診断使用および治療使用 - Google Patents

代謝活性プロフィルのモニタリング方法および分析方法ならびにそれらの診断使用および治療使用 Download PDF

Info

Publication number
JP5990254B2
JP5990254B2 JP2014503276A JP2014503276A JP5990254B2 JP 5990254 B2 JP5990254 B2 JP 5990254B2 JP 2014503276 A JP2014503276 A JP 2014503276A JP 2014503276 A JP2014503276 A JP 2014503276A JP 5990254 B2 JP5990254 B2 JP 5990254B2
Authority
JP
Japan
Prior art keywords
cell
cells
metabolic activity
disease
measuring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014503276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014512006A5 (enExample
JP2014512006A (ja
Inventor
ルーヴェン ティロシュ，
ルーヴェン ティロシュ，
フェルナンド パトルスキー，
フェルナンド パトルスキー，
ハギト ペレツ−ソロカ，
ハギト ペレツ−ソロカ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of JP2014512006A publication Critical patent/JP2014512006A/ja
Publication of JP2014512006A5 publication Critical patent/JP2014512006A5/ja
Application granted granted Critical
Publication of JP5990254B2 publication Critical patent/JP5990254B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Ecology (AREA)
JP2014503276A 2011-04-06 2012-04-04 代謝活性プロフィルのモニタリング方法および分析方法ならびにそれらの診断使用および治療使用 Active JP5990254B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472213P 2011-04-06 2011-04-06
US61/472,213 2011-04-06
PCT/IL2012/050125 WO2012137207A1 (en) 2011-04-06 2012-04-04 Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Publications (3)

Publication Number Publication Date
JP2014512006A JP2014512006A (ja) 2014-05-19
JP2014512006A5 JP2014512006A5 (enExample) 2015-05-14
JP5990254B2 true JP5990254B2 (ja) 2016-09-07

Family

ID=46124593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503276A Active JP5990254B2 (ja) 2011-04-06 2012-04-04 代謝活性プロフィルのモニタリング方法および分析方法ならびにそれらの診断使用および治療使用

Country Status (11)

Country Link
US (3) US8728758B2 (enExample)
EP (1) EP2694962B1 (enExample)
JP (1) JP5990254B2 (enExample)
KR (1) KR102010600B1 (enExample)
CN (1) CN103518133B (enExample)
AU (1) AU2012240953B2 (enExample)
BR (1) BR112013025782B1 (enExample)
CA (1) CA2832031C (enExample)
DK (1) DK2694962T3 (enExample)
ES (1) ES2627154T3 (enExample)
WO (1) WO2012137207A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012137207A1 (en) 2011-04-06 2012-10-11 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
US20160262693A1 (en) * 2013-10-14 2016-09-15 Case Western Reserve University Metabolic analyzer for optimizing health and weight management
US10274456B2 (en) 2013-10-22 2019-04-30 Ramot At Tel-Aviv University Ltd. Method and system for sensing
ITRM20130700A1 (it) * 2013-12-19 2015-06-20 Stichting Katholieke Univ Metodo per il rilevamento di cellule tumorali circolanti
CN105303035A (zh) * 2015-09-29 2016-02-03 上海新窝信息科技有限公司 一种健康监测方法及系统
RU2018124339A (ru) 2015-12-09 2020-01-09 Рамот Ат Тель-Авив Юниверсити Лтд. Способ и система для сенсорного обнаружения посредством модифицированной наноструктуры
RU2019108155A (ru) 2016-08-22 2020-09-21 Рамот Эт Тель-Авив Юниверсити Лтд. Способ и система для подкожного сенсорного определения
US11906463B2 (en) 2016-08-22 2024-02-20 Ramot At Tel-Aviv University Ltd. Methods and systems for detecting bioanalytes
JP7356412B2 (ja) 2017-08-21 2023-10-04 サヴィセル ダイアグノスティック リミテッド 肺癌を検出する方法
CN110491511B (zh) * 2019-07-24 2023-04-07 广州知汇云科技有限公司 一种基于围术期危险预警的多模型互补增强机器学习方法
IT202000016429A1 (it) * 2020-07-07 2022-01-07 Univ Degli Studi Udine Metodo per la valutazione dell’attivita’ metabolica di una cellula non-tumorale
EP4251997A4 (en) * 2020-11-26 2025-07-23 12535441 Canada Ltd SPECTRAL DIAGNOSTIC SYSTEM
US20240358835A1 (en) * 2021-08-17 2024-10-31 Orgenesis Inc. Tumor infiltrating lymphocytes with increased metabolic activity

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2457391A1 (en) * 2001-08-06 2003-02-20 Vanderbilt University Device and methods for detecting the response of a plurality of cells to at least one analyte of interest
JP4625946B2 (ja) * 2004-11-02 2011-02-02 国立大学法人 岡山大学 ｐＨ測定装置及びｐＨ測定方法
EP1736780A1 (en) * 2005-06-24 2006-12-27 Eppendorf Array Technologies S.A. Method and means for detecting and/or quantifying hierarchical molecular change of a cell in response to an external stimulus
JP2009526519A (ja) * 2006-01-17 2009-07-23 セルーメン、インコーポレイテッド 生物学的システム応答の予測方法
WO2007102146A2 (en) 2006-03-06 2007-09-13 Zetiq Technologies Ltd. Methods and compositions for identifying a cell phenotype
WO2011000572A1 (de) * 2009-07-02 2011-01-06 Patenthandel Portfoliofonds I Gmbh & Co. Kg Verfahren und vorrichtung zum nachweis von biologischen langzeiteffekten in zellen
EP2476053A4 (en) * 2009-09-08 2014-03-12 Nodality Inc ANALYSIS OF CELL NETWORKS
WO2012137207A1 (en) 2011-04-06 2012-10-11 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Also Published As

Publication number Publication date
US20140255972A1 (en) 2014-09-11
CN103518133A (zh) 2014-01-15
ES2627154T3 (es) 2017-07-26
BR112013025782B1 (pt) 2022-09-06
BR112013025782A2 (pt) 2016-12-20
CN103518133B (zh) 2016-08-17
CA2832031C (en) 2019-09-17
EP2694962B1 (en) 2017-03-01
EP2694962A1 (en) 2014-02-12
CA2832031A1 (en) 2012-10-11
AU2012240953B2 (en) 2017-02-23
KR102010600B1 (ko) 2019-08-13
US9784731B2 (en) 2017-10-10
DK2694962T3 (en) 2017-06-12
WO2012137207A1 (en) 2012-10-11
JP2014512006A (ja) 2014-05-19
US20130224789A1 (en) 2013-08-29
KR20140024871A (ko) 2014-03-03
US20180038849A1 (en) 2018-02-08
US8728758B2 (en) 2014-05-20
AU2012240953A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
JP5990254B2 (ja) 代謝活性プロフィルのモニタリング方法および分析方法ならびにそれらの診断使用および治療使用
Wang et al. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation
Vissink et al. Current and future challenges in primary Sjogren's syndrome
Ribeiro et al. Application of Raman spectroscopy for characterization of the functional polarization of macrophages into M1 and M2 cells
US20250022536A1 (en) Immune repertoire patterns
Lee et al. Use of a platform with lens-free shadow imaging technology to monitor natural killer cell activity
Bachmeier‐Zbären et al. Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy
Baraniuk et al. Meta-analysis of natural killer cell cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome
Rodriguez et al. Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy
Schroeder et al. Novel human kidney cell subsets identified by Mux-Seq
Sameir et al. The increased frequency of type 1 regulatory T (Tr1) cells and the altered expression of aryl hydrocarbon receptor (AHR) and interferon regulatory factor-4 (IRF4) genes in type 1 diabetes: a case-control study
Markov et al. Profibrotic monocyte-derived alveolar macrophages as a biomarker and therapeutic target in systemic sclerosis-associated interstitial lung disease
Russo et al. 1133p skin photoaging around the site of occurrence of primary melanoma as a clinical predictive biomarker of response to pd-1 inhibitors
Chen et al. Expression of regulatory T cells in driver-gene-negative advanced non-small cell lung cancer as well as its effect on the therapeutic efficacy and prognosis of immune checkpoint inhibitors
Antelo et al. Reduction of skin‐homing cytotoxic T cells (CD8+–CLA+) in patients with vitiligo
US12462941B2 (en) Pan-cancer tumor microenvironment classification based on immune escape mechanisms and immune infiltration
Kim Dissection of Macrophage Diversity in Hepatocellular Carcinoma Elucidates Molecular Correlates to aPD-1 Response
Sánchez-Menéndez et al. Differences in the peripheral blood immune landscape between early-onset and late-onset colorectal cancer
KR102044679B1 (ko) 이식 거부 반응 예측에 관한 정보제공방법
Duan et al. A case report and literature review of a rare lymphoma with repeated fever and pain, and numbness in both lower limbs
Zhou et al. Research Advances of Pan-Immune Inflammation Value (PIV) in Rheumatoid Arthritis
Arum et al. Predictors of mortality in children with neuroblastoma
Eriksson et al. 1135P Plasma proteomics in patients with metastatic cutaneous melanoma treated with targeted therapy
Ptacek et al. A Systems Immunology Approach Identifies Cytokine-Induced STAT Signaling Pathways Critical to Rheumatoid Arthritis Disease Activity and Treatment Response
ES3018832A1 (es) Células T EMRA como biomarcadores predictores de respuesta a la inmunoterapia en pacientes con cáncer de pulmón no microcítico

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160301

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160812

R150 Certificate of patent or registration of utility model

Ref document number: 5990254

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250